{"name":"M. Peter Marinkovich","slug":"m-peter-marinkovich","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2500000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Efgartigimod","genericName":"Efgartigimod","slug":"efgartigimod","revenue":2500000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":2500000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Efgartigimod","genericName":"Efgartigimod","slug":"efgartigimod","indication":"Immune thrombocytopenia","status":"marketed","revenue":2500000000}]}],"pipeline":[{"name":"Efgartigimod","genericName":"Efgartigimod","slug":"efgartigimod","phase":"marketed","mechanism":"Efgartigimod alfa binds to FcRn, reducing circulating IgG, while hyaluronidase increases subcutaneous permeability.","indications":["Immune thrombocytopenia","Myasthenia gravis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9wR2pPcjE1RjRZMWJTUEx6dnJuZFpSbmFxUktCOFV4N2trR3prNTFoYWZVdk9WTy1CUTVpQWZqU2c1d3U2a1RYUWgxbUN5cF9iT0VreS1CcHp1QU1zcGhqdnZ0bHlIcXpG?oc=5","date":"2024-12-11","type":"pipeline","source":"MedPage Today","summary":"Could Psoriasis Treatment Be This Simple? - MedPage Today","headline":"Could Psoriasis Treatment Be This Simple?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOOTFWcDVoVDdkWlN2c096eUJSQ0hoN1Q5cG5rN1dVM3VwTy0zZTAtVWo3dTBUOXY0SWdJX2JVZWRGaV90QmNmX1RoRnBBMzhLN0lYcGV5NERRRmZnWVIyY1hPZXJ3SmJPMjJTTWNvc2h1QnZhS0lKWFVaWmJqQUlIeTdPSkNwUkVuLUlyalNnSXRaOHVXOTgyaEFUeDdPWFVhSHNYMVdIUDE4SU9YTU9UaUV2dmxNUHBSc2N6VVUyUnJLQQ?oc=5","date":"2023-05-19","type":"regulatory","source":"Krystal Biotech, Inc","summary":"Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa - Krystal Biotech, Inc","headline":"Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) f","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE8yS2FsajJIMmg2NFU0NTEwX2REWDM0bWhITHozU1pUa0V0cW9sazFPU1VGV2hQVk5TN3A1UEE4WjI0YkEwbHdFSUNtTnI2QTJXMFdoVEU1cGpha01DNGdwTw?oc=5","date":"2022-12-14","type":"regulatory","source":"NEJM","summary":"Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa - NEJM","headline":"Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE04TkZfWHNnZmRsdzV2elNoNTNvQTA3SVJsOWhDVjhKcFFoS2lES1pDOHZRNkJldGxkdmN4S3lwMHBBUGVGa2lwT3VRQUNiUTNmcGxTVnhhWVN1RVpwZFUw?oc=5","date":"2022-03-28","type":"trial","source":"nature.com","summary":"In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial - nature.com","headline":"In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBpMl9hVlE4c2p6VnBJLVRpekQyVEZVSlZPQUIwRE9XUzgxRUxLWGt5VGE1bElhY3JQVVhqZzR3bU13Y3FuSWhSZjFQQ3pCa3lZQlkteTFsTFQzbjA4UDNoUkhVNXdUVElz?oc=5","date":"2012-04-16","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"People in the News - Genetic Engineering and Biotechnology News","headline":"People in the News","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}